<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2013">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356495</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2020/12</org_study_id>
    <nct_id>NCT04356495</nct_id>
  </id_info>
  <brief_title>Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19)</brief_title>
  <acronym>COVERAGE</acronym>
  <official_title>Outpatient Treatment of Elderly People With Symptomatic SARS-CoV-2 Infection (COVID-19): a Multi-arm, Multi-stage (MAMS) Randomized Trial to Assess the Efficacy and Safety of Several Experimental Treatments to Decrease the Risk of Hospitalization or Death (COVERAGE Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will estimate the efficacy and tolerance of several experimental treatments to
      prevent hospitalization or death in outpatients aged 60 years or above with Symptomatic
      SARS-CoV-2 Infection (COVID-19).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized controlled, open-label, multi-arm multi-stage (MAMS) trial.

      Participants will be randomly allocated 1:1 to the following strategies:

        -  Arm 1: control arm

        -  Arms 2 to X (where X is the number of arms): Experimental treatment At the time of trial
           initiation: People in the control arm will receive a complex of vitamins; people in the
           experimental arms will receive imatinib or telmisartan.

      Once the trial begins:

        -  If an experimental treatment proves to be effective before the end of the trial; it will
           become the new standard.

        -  Any experimental arm fulfilling the criteria for futility, efficacy or toxicity before
           the end of the trial will be prematurely terminated.

        -  New experimental arms may be added if new evidence suggests that other treatments should
           be tested.

      Participants will be followed 28 days. The primary outcome will be the proportion of
      participants with an occurrence of hospitalization or death between D0 and D14.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2020</start_date>
  <completion_date type="Anticipated">January 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase III multi-centre, open-label, randomized controlled superiority multi-arm multi-stage, (MAMS) trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with an occurrence of hospitalization</measure>
    <time_frame>From inclusion (day0) to day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>From inclusion (day0) to day 14</time_frame>
    <description>Proportion of participants with an occurrence of death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of hospitalizations, overall and by cause, in each group</measure>
    <time_frame>From inclusion (day0) to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death and causes of death</measure>
    <time_frame>From inclusion (day0) to day 28</time_frame>
    <description>Proportion of deaths, overall and by cause, in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of intensive care hospitalizations, overall and by cause, in each group</measure>
    <time_frame>From inclusion (day0) to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with negative nasopharyngeal SARS-CoV-2 RT-PCR</measure>
    <time_frame>day 7 and day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a loss of autonomy evaluated by the ADL and IADL scale</measure>
    <time_frame>day 14 and day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematological markers evolution</measure>
    <time_frame>from inclusion (day 0) to day 7 and day 14</time_frame>
    <description>Evolution of Haematological markers in each group : Complete Blood Count, prothrombin level, INR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical markers evolution</measure>
    <time_frame>from inclusion (day 0) to day 7 and day 14</time_frame>
    <description>Evolution of Biochemical markers in each group : ferritin, serum creatinine, urea, sodium, potassium, chlorine, calcium, magnesium, albumin, bicarbonates / tCO2, LDH, CPK, ASAT, ALAT, uricemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers evolution</measure>
    <time_frame>from inclusion (day 0) to day 7 and day 14</time_frame>
    <description>Evolution of Inflammatory markers in each group : PCT, CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological markers evolution</measure>
    <time_frame>from inclusion (day 0) to day 7 and day 14</time_frame>
    <description>Evolution of immunological markers in each group : B ans T Cells phenotypic profiles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>from inclusion (day 0) to day 14</time_frame>
    <description>Number and proportion of grade 1,2,3,4 adverse events in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions</measure>
    <time_frame>from inclusion (day 0) to day 14</time_frame>
    <description>Number and proportion of grade 1,2,3,4 adverse events in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration</measure>
    <time_frame>day 7</time_frame>
    <description>Plasma concentration of the study drugs at D7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of the treatment</measure>
    <time_frame>from inclusion (day 0) to day 10</time_frame>
    <description>Acceptability of the treatment by participant will be assessed with an interview</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">338</enrollment>
  <condition>Corona Virus Infection</condition>
  <condition>Sars-CoV2</condition>
  <arm_group>
    <arm_group_label>Vitamins</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients in this arm will receive a vitamin supplement (&quot;AZINC forme et vitalité®&quot;) during 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive Telmisartan (Micardis® 20 mg) during 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamins</intervention_name>
    <description>2 tablets daily from the first day (day 0) to day 9</description>
    <arm_group_label>Vitamins</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>1 tablet daily from the first day (day 0) to day 9</description>
    <arm_group_label>Telmisartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive SARS-CoV-2 infection virology test on nasopharyngeal swab

          -  Onset of symptoms &lt; 5 days prior to nasopharyngeal swab sampling

          -  Age ≥ 60 years

          -  Valid, ambulatory person, fully capable of understanding the challenges of the tria

          -  No hospitalization criteria according to current recommendations

          -  Signed informed consent

          -  Covered by Health Insurance

        Exclusion Criteria:

          -  Inability to make a decision to participate (dementia, guardianship)

          -  Long QT syndrome, or QTc space &gt; 500 ms

          -  Presence of a pace maker

          -  Heart rate &lt;50 / min

          -  Hyperkalemia &gt; 5.5 mmol/L or hypokalemia &lt; 3.5 mmol/L

          -  Treatment with dasatinib, nilotinib, ibrutinib, potent inhibitors of cytochrome P450
             CYP3A4 isoenzyme, potent inducers of cytochrome P450 CYP3A4 isoenzyme, warfarin

          -  Hypersensitivity to any of the trial drugs, ARA2 or sartan.

          -  Liver failure (stage ≥ Child-Pugh B), stage 4 or 5 chronic kidney disease (DFG &lt;30
             mL/min/1.73 m²), person on dialysis, malabsorption syndrome, ileus, colitis or
             enterocolitis, chronic infection with the hepatitis B virus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis MALVY, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier ANGLARET, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Inserm 1219</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura RICHERT, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denis MALVY, Pr</last_name>
    <phone>0557822796</phone>
    <phone_ext>+33</phone_ext>
    <email>denis.malvy@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xavier ANGLARET, Dr</last_name>
    <phone>0557571258</phone>
    <phone_ext>+33</phone_ext>
    <email>xavier.anglaret@u-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH de Bastia</name>
      <address>
        <city>Bastia</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas DARNAUD, Dr</last_name>
      <email>thomas.darnaud@ch-bastia.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux university Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis MALVY, Pr</last_name>
      <phone>05 57 82 27 96</phone>
      <phone_ext>+33</phone_ext>
      <email>denis.malvy@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Xavier ANGLARET, Dr</last_name>
      <phone>0557571258</phone>
      <phone_ext>+33</phone_ext>
      <email>xavier.anglaret@u-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon-Bourgogne</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel PIROTH, Pr</last_name>
      <email>lionel.piroth@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin LEFEVRE, Dr</last_name>
      <email>B.LEFEVRE@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie DUPOUY, Dr</last_name>
      <email>julie.dupouy@dumg-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 11, 2020</study_first_submitted>
  <study_first_submitted_qc>April 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Corona virus</keyword>
  <keyword>Sars-CoV2</keyword>
  <keyword>telmisartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

